🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSTEP-HFpEF: semaglutide in heart failure with preserved EF — March 2026 Page 5

STEP-HFpEF: semaglutide in heart failure with preserved EF — March 2026

GenomicsKate Wed, Jun 4, 2025 at 7:34 PM 38 replies 1,967 viewsPage 5 of 8
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Jul 10, 2025 at 4:50 AM#21

One concrete data point for the thread. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.

Happy to go further on any of that.

Last edited: Jul 10, 2025 at 10:50 AM
32 7MikeFit_NJ, InsuranceTom, WendyG_ATL and 29 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Jul 22, 2025 at 11:02 AM#22

One thing that is still open after sophie_paris’s answer:

What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?

31 6TrialTracker_MD, JennaRN, LabKate and 28 others
Reply Quote Save Share Report
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Aug 3, 2025 at 5:07 PM#23
Dr.PathRoch said:
For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…
Dr.PathRoch said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

30 5mia_MS2, LeilaHI, marcus_mpls and 27 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Aug 15, 2025 at 11:05 PM#24
Dr.PathRoch said:
For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

Senior perspective on cardiovascular risk: I'm 70 years old and started this journey skeptically. My internist recommended it after years of failed interventions.

8 months later: down 53 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

Last edited: Aug 16, 2025 at 3:05 AM
29 4ricardo_MIA, BrianDallas92, labquiet_amy and 26 others
Reply Quote Save Share Report
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Aug 28, 2025 at 4:56 AM#25
Dr.PathRoch said:
For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

This answered a question I did not know how to ask.

Last edited: Aug 28, 2025 at 5:56 AM
28 3RickReta_CO, PharmHunterJen, TomTeleRx and 25 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register